1345835-12-2
Chemical Structure
ZP3022
- CAS No.: 1345835-12-2
- Formula:C199H294N48O61S
- Molecular Weight:4366.81
SMILES: O=C(NCCOCCOCC(N[C@@H](CC1=CC=C(C=C1)O)C(NCC(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N)=O)=O)=O)=O)=O)=O)=O)COCCOCCNC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC5=CNC6=CC=CC=C56)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC7=CC=CC=C7)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC8=CC=CC=C8)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(CNC([C@H](CC9=CNC=N9)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: ZP3022 is a dual GLP-1R/CCK-2R agonist. ZP3022 enhances insulin secretion, improves glycemic control and glucose tolerance, lowers blood glucose and HbA1c levels, reduces food intake and body weight, and inhibits gastric emptying. ZP3022 does not activate CCK-1R. ZP3022 can be used in research on diabetes and obesity[1][2][3][4][5][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ZP3022 | 98.00% | ZP3022 is a dual GLP-1R/CCK-2R agonist. ZP3022 enhances insulin secretion, improves glycemic control and glucose tolerance, lowers blood glucose and HbA1c levels, reduces food intake and body weight, and inhibits gastric emptying. ZP3022 does not activate CCK-1R. ZP3022 can be used in research on diabetes and obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen X, et al. Stapled and Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes. Journal of medicinal chemistry. 2020 Nov 12;63(21):12595-12613.
- [2]. Neumann J, et al. Future GLP-1 receptor co-agonists and their cardiac effects. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026 Sep 22:1-5.
- [3]. Yang Q, et al. Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y Receptor Agonists. Journal of medicinal chemistry. 2022 Oct 27;65(20):14201-14220.
- [4]. Liu X, et al. Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y receptor tri-agonist for obesity and type 2 diabetes. International journal of biological macromolecules. 2025 Nov;328(Pt 1):147553.
- [5]. Hao S, et al. Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects. The Journal of pharmacy and pharmacology. 2014 Aug;66(8):1133-9.
- [7]. English A, et al. Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions. Clinical medicine insights. Endocrinology and diabetes. 2019;12:1179551419888871.
